Icon PLC
✦ Quant Fair Value how this is computed
- Implied fair-value range of 12.67-349.70, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +3.1% above the average-multiple fair value of 181.18.
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Icon PLC (ICLR) | 13.99B | 32.41 | 1.53 | 0.00% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 3.6% above Morningstar's fair value estimate.
Analyst note
Icon reported third-quarter net business wins of $3.15 billion, a net book/bill ratio of 1.56 times, and a closing backlog of $24.5 billion, up 4.8% sequentially. Management raised 2026 revenue guidance by 1.9% at the midpoint and maintained its adjusted earnings per share midpoint of $10.50.
Why it matters: Icon delivered further evidence that its commercial recovery is beginning to translate into stronger financial performance. This marked the fourth consecutive quarter of net book/bill above 1.3 times, and direct fee revenue returned to sequential growth. Direct fee revenue reflects Icon's core service work and excludes lower-margin pass-through costs, so we view its improvement as a sign that healthy biotech funding and improving demand are beginning to translate into durable growth ahead of 2027. Adjusted gross margin expanded 90 basis points sequentially to 24.7%, driven by favorable business mix and tighter cost discipline rather than pricing. We view this as an encouraging sign that operating leverage is beginning to emerge, with earnings improving even before revenue growth meaningfully accelerates.
The bottom line: We increased our fair value estimate to $180 per share from $155 for no-moat Icon after improving our near-term revenue and profitability outlook. We forecast $8.16 billion of 2026 revenue, representing a 1.1% year-over-year decline, partially driven by headwinds from the divestiture of Symphony Health Solutions and the lingering drag of weak bookings in 2024 and 2025 on organic growth. While revenue is declining this year, we anticipate Icon's elevated book/bill ratio and improving business mix will lead to mid-single-digit compound annual revenue growth over 2027-31. Shares are currently trading about 20% above our valuation, implying an even more optimistic outlook.
BLANK PAGEFor details on the contract research organization industry, please see our 2026 Industry Landscape, "Contract
Research Organizations & Contract Development and Manufacturing Organizations."
Fair value
We are increasing our fair value estimate to $180 per share from $155 as we improve our near-term revenue and profitability outlook.
While near-term financial performance remains constrained by mix-related margin pressure from elevated pass-through activity, we see positive signs, driven by improving biotech funding levels and higher win rates in large pharma. Icon was working through a challenging macroeconomic environment over the past couple of years, as some of its customers were undergoing budget cuts and reprioritizations of their pipeline candidates. Management remains focused on driving operational utilization and cost control measures.
We forecast $8.16 billion in 2026 revenue, representing a 1.1% year-over-year decline, partially driven by headwinds from the divestiture of Symphony Health Solutions and the lingering drag of weak bookings in 2024 and 2025 on organic growth. While revenue is declining this year, we anticipate Icon's elevated book/bill ratio and improving business mix will lead to mid-single-digit compound annual revenue growth over 2027-31. We anticipate outsourced clinical development from biotech and pharma companies should drive growth for large contract research organizations like Icon.
We are encouraged by management's commentary that biotech customers are advancing into larger and more complex later-stage development programs, while Icon continues to expand its preferred-provider relationships across pharma and biotech customers. We believe these trends should support a higher-quality backlog, better revenue visibility, and a more durable growth outlook over time.
Headquartered in Ireland, the company benefits from a lower tax rate than its US peers. We forecast a long-term tax rate of about 15%. We assume midcycle capital expenditures will be about 2% of sales.
Economic moat
We believe Icon warrants a no-moat rating. While the firm operates on a global scale and maintains expertise in clinical trials and regulatory processes, we no longer view its advantages as durable enough to maintain excess economic returns over a 10-year time horizon to support a narrow moat rating. Having the most impact, Icon’s 2021 acquisition of PRA Health Sciences appears to have been value-destructive to the firm’s returns on invested capital. There has also been increased competition among large CROs and questions surrounding Icon’s market share during its ongoing accounting investigation.
Icon significantly expanded its scale in 2021 through the $12 billion acquisition of PRA Health Sciences. The transaction combined two large CROs and broadened Icon’s geographic footprint and service offerings. Icon paid roughly a 30% premium for PRA Health and assumed a substantial amount of goodwill and intangible assets on its balance sheet. Management initially targeted cost synergies and operational efficiencies from the combination, but the company’s adjusted returns on invested capital have declined meaningfully since the transaction (below our WACC of 8.7% since 2021 and estimated to remain below until 2033). In our view, the size of the purchase price relative to the realized synergies suggests the acquisition has diluted economic returns rather than strengthened Icon’s competitive position. While the deal expanded Icon’s geographic footprint and offerings, we do not believe the benefits justify the capital invested.
Over the past couple of years, Icon’s business performance has reflected a more cyclical demand environment with rising cancellations. Following strong demand during the pandemic period, clinical development spending has moderated as biotech funding slowed and large pharmaceutical firms became more selective with trial initiations. In 2024, Icon reported 2% revenue growth with modest earnings expansion and entered 2025 with continued demand uncertainty amid soft biotech funding levels and customers delaying their clinical development decisions.
Recently, operational uncertainty has increased following an internal investigation into the company’s accounting practices in February 2026, which is related to Icon’s revenue recognition between 2023 and 2025. The probe, which could involve revenue overstatements of less than 2% in 2023-24, prompted the company to withdraw its 2025 financial guidance and delay its financial reporting. The disclosure contributed to a 40% decline in the company’s share price and heightened investor concerns about governance and financial controls, plus there are multiple securities fraud class-action lawsuits filed against the firm.
Our low-single-digit sales forecast is driven less by the mechanical revenue correction and more by second-order effects, such as competitive pressure leading to potential market share loss during the investigation period (2023-25), slower bookings, reputational risks, and internal control concerns. If Icon faces market share pressure, it will need to offer discounts to win future business and accept lower-margin contracts, which would reduce growth over the next several years. Even modest market share slippage in the competitive CRO market can dampen the growth trajectory for several years, and that lower revenue base compounds over time.
Icon’s scale, capabilities, and established client relationships should allow the company to retain a share of industry demand within the CRO market. However, we do not expect Icon’s adjusted returns on invested capital to be consistently above its weighted average cost of capital over the long term, which reinforces our no-moat rating.
Bull case
If biotech funding recovers and clinical trial starts increase, this could improve bookings growth, lower cancellations, and return to mid‑single‑digit revenue growth.
If the accounting probe concludes with immaterial restatements and Icon rebounds with stronger near-term revenue growth, investor confidence could be restored.
As an Irish company, Icon benefits from a lower tax rate than many of its peers based in the United States.
Bear case
Drawbacks to biotech funding or declines in outsourcing penetration rates could have a material impact on Icon's growth.
Icon could fail to innovate and keep an edge over regional and global CRO competitors, especially as data and analytics play an increasing role in clinical development.
Competitive pressure could force Icon to accept lower‑margin contracts to retain or win business, which could constrain growth.
By Rachel Elfman
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Icon PLC discussion 0 comments